Literature DB >> 18199559

Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis.

Nabiha Yusuf1, Tahseen H Nasti, J Alan Long, Mohammed Naseemuddin, Alan P Lucas, Hui Xu, Craig A Elmets.   

Abstract

Toll-like receptors (TLR) activate multiple steps in inflammatory reactions in innate immune responses. They also activate signals that are critically involved in the initiation of adaptive immune responses. Many tumorigenic chemicals have been associated with endotoxin hypersensitivity mediated through TLR4. To determine the role of TLR4 in cutaneous skin carcinogenesis, we treated TLR4-deficient C3H/HeJ mice and the TLR4-normal C3H/HeN mice with the carcinogenic polyaromatic hydrocarbon 7,12-dimethylbenz(a)anthracene (DMBA). TLR4-deficient C3H/HeJ mice developed more tumors relative to the TLR4-normal C3H/HeN mice. Both C3H/HeN and C3H/HeJ mice developed a T-cell-mediated immune response to topically applied DMBA. Interestingly, the cell-mediated immune response was mediated by IFN-gamma in C3H/HeN mice and by interleukin (IL)-17 in C3H/HeJ mice. Moreover, C3H/HeN mice had elevated circulating levels of IFN-gamma following topical application of DMBA, whereas IL-17 was elevated in C3H/HeJ mice. The results of this study indicate that TLR4 plays an important role in the prevention of DMBA skin tumorigenesis and that this is associated with differences in the T-cell subtype activated. Efforts to divert the cell-mediated immune response from one that is IL-17 mediated to one that is IFN-gamma mediated may prove to be beneficial in the prevention of DMBA-induced cutaneous tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199559      PMCID: PMC3568948          DOI: 10.1158/0008-5472.CAN-07-5219

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells.

Authors:  Hironori Matsushima; Nobuo Yamada; Hiroyuki Matsue; Shinji Shimada
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

2.  Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells.

Authors:  Hiroshi Mitsui; Takahiro Watanabe; Hidehisa Saeki; Katsunori Mori; Hideki Fujita; Yayoi Tada; Akihiko Asahina; Koichiro Nakamura; Kunihiko Tamaki
Journal:  J Invest Dermatol       Date:  2004-01       Impact factor: 8.551

Review 3.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

4.  Interleukin-17 promotes angiogenesis and tumor growth.

Authors:  Muneo Numasaki; Jun-ichi Fukushi; Mayumi Ono; Satwant K Narula; Paul J Zavodny; Toshio Kudo; Paul D Robbins; Hideaki Tahara; Michael T Lotze
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

5.  Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism.

Authors:  Fabrice Benchetrit; Arnaud Ciree; Virginie Vives; Guy Warnier; Alain Gey; Catherine Sautès-Fridman; François Fossiez; Nacilla Haicheur; Wolf H Fridman; Eric Tartour
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

6.  IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis.

Authors:  M C Honorati; S Neri; L Cattini; A Facchini
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

7.  Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts.

Authors:  Muneo Numasaki; Michael T Lotze; Hidetada Sasaki
Journal:  Immunol Lett       Date:  2004-04-30       Impact factor: 3.685

8.  Expression of functional Toll-like receptor 2 on human epidermal keratinocytes.

Authors:  Kazuhiro Kawai; Hideki Shimura; Masahiro Minagawa; Akiko Ito; Katsuhiro Tomiyama; Masaaki Ito
Journal:  J Dermatol Sci       Date:  2002-12       Impact factor: 4.563

Review 9.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 10.  Toll-like receptors and their signaling mechanisms.

Authors:  Shizuo Akira; Shintaro Sato
Journal:  Scand J Infect Dis       Date:  2003
View more
  38 in total

Review 1.  Toll-like receptors and cancer.

Authors:  Seth Rakoff-Nahoum; Ruslan Medzhitov
Journal:  Nat Rev Cancer       Date:  2008-12-04       Impact factor: 60.716

Review 2.  Application of angiogenesis to clinical dermatology.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Adv Dermatol       Date:  2008

3.  TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.

Authors:  Deepak Mittal; Fabiana Saccheri; Emilie Vénéreau; Tobias Pusterla; Marco E Bianchi; Maria Rescigno
Journal:  EMBO J       Date:  2010-06-04       Impact factor: 11.598

4.  Differential innate immune cell signatures and effects regulated by toll-like receptor 4 during murine lung tumor promotion.

Authors:  Carla-Maria Alexander; Ka-Na Xiong; Kalpana Velmurugan; Julie Xiong; Ross S Osgood; Alison K Bauer
Journal:  Exp Lung Res       Date:  2016-04       Impact factor: 2.459

Review 5.  Early immune events in the induction of allergic contact dermatitis.

Authors:  Daniel H Kaplan; Botond Z Igyártó; Anthony A Gaspari
Journal:  Nat Rev Immunol       Date:  2012-01-13       Impact factor: 53.106

6.  TLR4 in skin cancer: From molecular mechanisms to clinical interventions.

Authors:  Sally E Dickinson; Georg T Wondrak
Journal:  Mol Carcinog       Date:  2019-04-24       Impact factor: 4.784

Review 7.  Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?

Authors:  Li Yu; Liantang Wang; Shangwu Chen
Journal:  Cell Mol Life Sci       Date:  2011-11-03       Impact factor: 9.261

Review 8.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

9.  Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis.

Authors:  Nabiha Yusuf; Tahseen H Nasti; Sreelatha Meleth; Craig A Elmets
Journal:  Mol Carcinog       Date:  2009-08       Impact factor: 4.784

10.  Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis.

Authors:  Alison K Bauer; Jennifer Fostel; Laura M Degraff; Elizabeth A Rondini; Christopher Walker; Sherry F Grissom; Julie Foley; Steven R Kleeberger
Journal:  Mol Cancer       Date:  2009-11-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.